Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NTCD-M3
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Destiny Pharma
Deal Size : $570.0 million
Deal Type : Collaboration
Agreement with Sebela Pharmaceuticals for NTCD-M3
Details : Under the terms of the deal, Sebela will lead the future clinical development and commercialisation activities of NTCD-M3 in North America. NTCD-M3 is a naturally occurring non-toxigenic strain of C. difficile which lacks the genes that can express C. di...
Brand Name : NTCD-M3
Molecule Type : Large molecule
Upfront Cash : $1.0 million
February 24, 2023
Lead Product(s) : NTCD-M3
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Destiny Pharma
Deal Size : $570.0 million
Deal Type : Collaboration
Lead Product(s) : Tegoprazan
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Recipient : BRAINTREE LABS
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Tegoprazan (CJ-12420) is a novel agent in development for the treatment of acid-related gastrointestinal diseases. Tegoprazan has already received marketing authorization in multiple territories, including South Korea and China.
Brand Name : CJ-12420
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 19, 2022
Lead Product(s) : Tegoprazan
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Recipient : BRAINTREE LABS
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?